About AAVANTIBio
AAVANTIBio is a Healthcare company based in Gainesville (United States) founded in 2017, and was acquired by Solid Biosciences in September 2022. Gene transfer therapies for neuromuscular diseases are developed. AAVANTIBio has raised $107 million across 1 funding round from investors including Solid Biosciences, Sarepta Therapeutics and Bain Capital. Its focus areas include Life Sciences, Gene Therapy, Diversified and Neurology. Its competitors include Senti Biosciences, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
AAVANTIBio was founded in 2017 and is based in Gainesville, United States. Focus is placed on biotechnology within the gene therapy sector. Gene-editing technologies are developed to target fatal neuromuscular conditions. Operations center on AAV-mediated gene transfer approaches, with the lead program directed at Friedreichs ataxia. Research and development activities aim to address unmet needs in disease treatment through innovative delivery methods.
- Headquarters Gainesville, United States
- Stage Acquired
- SectorsHealthcare
- Website aavantibio.com
- Social LinkedIn X
- Acquired by Solid Biosciences (Sep 2022)
- Total Equity Funding$107M (USD)
in 1 rounds
- Latest Funding Round$107M (USD), Series A
Oct 2020
- InvestorsSolid Biosciences
& 4 more
- Acquired bySolid Biosciences
(Sep 2022)
Funding Insights of AAVANTIBio
AAVANTIBio has successfully raised a total of $107M through 1 strategic funding round. The most recent funding activity was a Series A round of $107 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $107M
- Total Rounds 1
- Last Round Series A — $107M
- First Round $107M
(Oct 2020)
- Investors Count 4
All 1 funding rounds of AAVANTIBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $107M | Series A | – | Perceptive Advisors, Bain Capital | – |
5 investors in total: 5 institutional.
Investors in AAVANTIBio
AAVANTIBio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Solid Biosciences, Sarepta Therapeutics and Bain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Debt and equity investments are pursued across multiple sectors. | 1984 | baincapital.com | Boston, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
RNA-targeted therapeutics are developed for rare and infectious diseases. | 1980 | sarepta.com | Cambridge, United States | |
Gene therapy platform for Duchenne muscular dystrophy is developed. | 2014 | solidbio.com | Cambridge, United States |
Investor details for AAVANTIBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AAVANTIBio
44 people are tracked at AAVANTIBio (27 in leadership, 8 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Bo Cumbo | President & CEO | Leadership |
Ty Howton | Chief Administrative Officer | Leadership |
Jessie Hanrahan | Chief Regulatory And Preclinical Operations Officer | Leadership |
Paul Herzich | CTO | Leadership |
Kathleen Kelly | Senior Director, Corporate Controller | Leadership |
Melanie Von Schimmelmann | Vice President, Portfolio And Program Management | Leadership |
Brian Hughes | Vice President | Head Of Human Resources | Leadership |
Resham Banga | Associate Director | Leadership |
Elizabeth Crawford | Senior Director, Portfolio And Program Management | Leadership |
Kevin T. | Chief Financial Officer | Leadership |
Sarah Stelzleni | Executive Director, Regulatory | Leadership |
Carol Lahiff | Associate Director, Fp&a | Leadership |
Bigue N.konte | Associate Director Fp&a | Leadership |
Nilay Patel | Director, Vector Supply And Innovation | Leadership |
Keith Clark | Senior Director Information Technology | Leadership |
Oyinade Adefuye | Director Of Program Management | Leadership |
Nicoleta Stoicea | Medical Director, Clinical Development | Leadership |
Allison Bogosian | Svp, Head Of Human Resources & Administrative Operations | Leadership |
Kevin Tan | CFO | Leadership |
Ryan Cole | Director Of Accounting | Leadership |
24 more people are available in the full profile.
Complete people profiles for AAVANTIBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AAVANTIBio
3 dated milestones of AAVANTIBio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded AAVANTIBio is founded.
- Funding First funding round of $107.0M.
- Exit Acquired by Solid Biosciences.
Competitors of AAVANTIBio
AAVANTIBio has 3 listed competitors in our database, 3 of them funded. They include Senti Biosciences, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. | ||
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of AAVANTIBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AAVANTIBio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aavantibio
Complete news archive for AAVANTIBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AAVANTIBio
AAVANTIBio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
AAVANTIBio is headquartered in Gainesville, United States.
AAVANTIBio is a funded company, having raised a total of $107M across 1 funding round to date. The company's 1st funding round was a Series A of $107M, raised on Oct 2020.
AAVANTIBio was founded in 2017 and is based in Gainesville, United States. Focus is placed on biotechnology within the gene therapy sector. Gene-editing technologies are developed to target fatal neuromuscular conditions. Operations center on AAV-mediated gene transfer approaches, with the lead program directed at Friedreichs ataxia. Research and development activities aim to address unmet needs in disease treatment through innovative delivery methods.
AAVANTIBio's top competitors include PTC Therapeutics, Neurocrine and Senti Biosciences.
AAVANTIBio has 5 investors. Key investors include Solid Biosciences, Sarepta Therapeutics, Bain Capital, RA Capital, and Perceptive Advisors.
Yes. AAVANTIBio was acquired by Solid Biosciences in September 2022.